AI Health Index: Clinical Decision Support changes https://aihealthindex.io/categories/clinical-decision-support Material product changes at Clinical Decision Support vendors, tracked by AI Health Index. Every entry is dated and cited to a public source. en-us Free to reuse with a visible link to aihealthindex.io. Terms: https://aihealthindex.io/use-this-data Thu, 24 Sep 2026 12:00:00 GMT 720 https://aihealthindex.io/icon-192.png AI Health Index: Clinical Decision Support changes https://aihealthindex.io/categories/clinical-decision-support InsightRX released Gemini 2026.2, an update to the model selection engine in InsightRX Nova that adds a new general adult vancomycin… https://aihealthindex.io/changelog/insightrx aihealthindex.io:change:6ab90c10ee3c2977980e6544 Thu, 24 Sep 2026 12:00:00 GMT Model / architecture Medication Safety & Prescribing Clinical Decision Support InsightRX released Gemini 2026.2, an update to the model selection engine in InsightRX Nova that adds a new general adult vancomycin model, McCarthy 2026, plus CKD-EPI eGFR versions of the published models that improved with that input. McCarthy 2026 was fit on a stratified sample drawn from 549,171 patients across 304 US organizations, scales body size on fat free mass and bends the eGFR effect on clearance at 90 mL/min/1.73 m2. InsightRX reports that the release raised individual prediction accuracy from 66% to 68%, cut bias (MPE) from 1.8% to 0.9% and cut error (NRMSE) from 28% to 27% versus Gemini 2026.1.

Why it matters: Health systems using Gemini get the new model recommendations automatically, and InsightRX states the Hughes 2024 obesity model is now mostly selected only for patients with obesity. It also shows the vendor retraining and revalidating models on network data after deployment. The accuracy gains are vendor reported and modest.

Impact: Medium. Verification: Verified. Type: Model / architecture.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Aidoc received FDA Breakthrough Device Designation for CARE Chest X-Ray Triage, built on its CARE foundation model, covering triage of… https://aihealthindex.io/changelog/aidoc aihealthindex.io:change:6ab85e9bd92e5616ac6dc814 Wed, 23 Sep 2026 12:00:00 GMT Regulatory / FDA Radiology & Imaging AI Clinical Decision Support Health System AI Platforms Aidoc received FDA Breakthrough Device Designation for CARE Chest X-Ray Triage, built on its CARE foundation model, covering triage of pneumomediastinum and lobar or lung collapse. It is Aidoc's third breakthrough designation in just over a year, after CARE Multi-Triage Body CT and CARE First Read for Chest X-Ray. The 510(k) is under FDA review and the product is not yet available for sale in the United States.

Why it matters: A breakthrough designation can speed FDA review but does not clear the product. Radiology groups interested in foundation model triage for chest films should treat this as a roadmap signal and ask Aidoc for expected clearance timing.

Impact: Medium. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Doximity Ask: Doximity published Bedside Bench, an open source clinical AI benchmark of 500 cases across 10 sub benchmarks, including drug safety… https://aihealthindex.io/changelog/doximity-ask aihealthindex.io:change:6ab90c10ee3c2977980e653c Tue, 22 Sep 2026 12:00:00 GMT Clinical evidence Clinical Reference & Evidence Healthcare Administrative Automation Clinical Decision Support Doximity published Bedside Bench, an open source clinical AI benchmark of 500 cases across 10 sub benchmarks, including drug safety, guideline adherence, landmark trials, hallucination and false premises, health equity and diagnostic safety. The 250 case training split and the grading rubrics are public on Hugging Face, and the test split is held out. Bedside Bench is one of the domain benchmarks in Fireworks' Specialized Intelligence Index, and Doximity states that Doximity Ask ranked first against frontier models when Fireworks graded it.

Why it matters: Buyers get a public rubric they can run against Doximity Ask and competing clinical reference tools. The ranking is stated without published scores and the benchmark was written by Doximity, so ask for the per benchmark numbers before relying on it.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Atropos Health states it expanded its federated Atropos Evidence Network to cover over 330 million U.S. patients, including more than 150… https://aihealthindex.io/changelog/atropos-health aihealthindex.io:change:6ab90c10ee3c2977980e653a Tue, 22 Sep 2026 12:00:00 GMT Product / capability Clinical Reference & Evidence Clinical Trials AI Clinical Decision Support Atropos Health states it expanded its federated Atropos Evidence Network to cover over 330 million U.S. patients, including more than 150 million EHR records with clinical notes, and added imaging and omics data linked to clinical outcomes and mortality through data partners including Norstella, Arcadia and OneMedNet. The network is queried through ChatRWD, Green Button and GENEVA OS, with the Real World Fitness Score grading data quality per question. The company claims temporal queries run up to 50 times faster and 30 times cheaper than traditional analytics; no method for that comparison is published.

Why it matters: Health systems and life sciences teams generating real world evidence can now study questions that need imaging or genomic context alongside EHR and claims data. The speed and cost figures are vendor claims without a stated baseline, so ask for the comparison behind them.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Cohere Health published performance results for Cohere Capture, which extracts HEDIS gap closures and denominator exclusions from clinical… https://aihealthindex.io/changelog/cohere-health aihealthindex.io:change:6ab85e9bd92e5616ac6dc810 Tue, 22 Sep 2026 12:00:00 GMT Clinical evidence RCM & Prior Auth AI Clinical Decision Support Cohere Health published performance results for Cohere Capture, which extracts HEDIS gap closures and denominator exclusions from clinical data a health plan already holds, including prior authorization notes, imaging reports and EHR data. Cohere reports an average 15 percent improvement in Stars performance per measure, 107 gaps closed per 1,000 members with records, and a minimum 5 to 1 return on a pay for performance model.

Why it matters: These figures are vendor reported and the release does not describe how they were measured. Plans should ask for the method and baseline behind the 15 percent figure, and how much of the lift comes from prior authorization records Cohere already sees as the plan's utilization management vendor.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Alcidion: Miya Precision 7.11.0 introduces a three tier restricted access model for patient records: full access, break glass access that requires… https://aihealthindex.io/changelog/alcidion aihealthindex.io:change:6ab90c10ee3c2977980e6539 Mon, 21 Sep 2026 12:00:00 GMT Security / compliance Hospital & Unit Operations Clinical Decision Support Health System AI Platforms Miya Precision 7.11.0 introduces a three tier restricted access model for patient records: full access, break glass access that requires justification via an individual PIN with audit tracking, and no access. Alcidion states the design supports NHS safeguarding principles.

Why it matters: Privacy and information governance teams get record level access control with an audited break glass path, which matters for restricted and safeguarding sensitive patients.

Impact: Low. Verification: Verified. Type: Security / compliance.

Evidence: Vendor documentation

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Alcidion's Miya Precision 7.11.0 adds a native inpatient admissions workflow, completing its admission, transfer, leave and discharge set… https://aihealthindex.io/changelog/alcidion aihealthindex.io:change:6ab90c10ee3c2977980e6538 Mon, 21 Sep 2026 12:00:00 GMT EHR / interoperability Hospital & Unit Operations Clinical Decision Support Health System AI Platforms Alcidion's Miya Precision 7.11.0 adds a native inpatient admissions workflow, completing its admission, transfer, leave and discharge set, with one way or two way integration to the Patient Administration System so clinicians no longer need to open the PAS. The release also adds Miya Vitals, for capturing observations on charts defined per care area such as ICU, ED and general wards with validation checks and warning thresholds, and Dynamic Fluid Balance Management, which calculates fluid restriction limits from patient weight.

Why it matters: Trusts running a separate PAS can manage the full inpatient encounter in Miya Precision while keeping the PAS in sync, which cuts double entry. Vitals capture is manual entry only in this release; Alcidion states capture from bedside monitors is planned for a future release.

Impact: Medium. Verification: Verified. Type: EHR / interoperability.

Evidence: Vendor documentation

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> AZmed received its sixth FDA clearance, for AZchest to detect and localize pneumothorax and pleural effusion on chest radiographs. https://aihealthindex.io/changelog/azmed aihealthindex.io:change:6aaeaddaaaa02078636c9cae Tue, 15 Sep 2026 12:00:00 GMT Regulatory / FDA Radiology & Imaging AI Clinical Decision Support AZmed received its sixth FDA clearance, for AZchest to detect and localize pneumothorax and pleural effusion on chest radiographs. That brings its Rayvolve suite to eight FDA cleared findings, and AZchest can now flag up to five findings on a single chest image.

Why it matters: Pneumothorax is a time critical miss, which is why this clearance matters more than the count. AZmed cites reading time reductions of up to 31 percent for readers outside thoracic radiology; that is the group to test it with, since specialist readers gain least.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Veracyte acquired Convergent Genomics, adding the UroAmp urine tumor DNA test to its urology portfolio. https://aihealthindex.io/changelog/veracyte aihealthindex.io:change:6aaeaddaaaa02078636c9cb7 Mon, 14 Sep 2026 12:00:00 GMT Acquisition / corporate Diagnostics & Genomics Clinical Decision Support Veracyte acquired Convergent Genomics, adding the UroAmp urine tumor DNA test to its urology portfolio. Veracyte can now offer genomic testing from urine, tissue and blood across bladder cancer care.

Why it matters: A urine test can help monitor bladder cancer between cystoscopies, the procedure patients most want to avoid. Urologists should ask how UroAmp results will be reported alongside Veracyte's existing tests, and whether ordering stays the same during the integration.

Impact: Medium. Verification: Verified. Type: Acquisition / corporate.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Abridge launched pre bill review for clinical documentation integrity, coding and revenue cycle teams. https://aihealthindex.io/changelog/abridge aihealthindex.io:change:6aaeaddaaaa02078636c9cb5 Mon, 14 Sep 2026 12:00:00 GMT Product / capability Ambient Scribes RCM & Prior Auth AI Clinical Decision Support Abridge launched pre bill review for clinical documentation integrity, coding and revenue cycle teams. It checks inpatient claims before submission, comparing the coded diagnoses and DRG against what the clinical record supports, including what was captured in the encounter, and surfaces discrepancies with the evidence. Abridge does not change documentation, codes or claim status; the CDI team decides what to hold, correct or release.

Why it matters: This takes Abridge from the exam room into the revenue cycle, where CDI vendors have worked for years. The advantage it claims is the encounter itself: a coder can see what was actually discussed, not just what was written. Ask how discrepancies are ranked, and how often a flag leads to a correction rather than a physician query.

Impact: High. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Canary Speech: Canary Ambient for Physicians is generally available inside Microsoft Dragon Copilot, listed on the Microsoft Marketplace as part of the… https://aihealthindex.io/changelog/canary-speech aihealthindex.io:change:6aa5b27795f1c7683c18cf6b Fri, 04 Sep 2026 12:00:00 GMT EHR / interoperability Behavioral Health AI Clinical Decision Support Remote Monitoring & Chronic Care Canary Ambient for Physicians is generally available inside Microsoft Dragon Copilot, listed on the Microsoft Marketplace as part of the Dragon Copilot AI Apps and Agents program Microsoft opened on 21 August. Inside the Dragon workflow, Canary analyses the acoustic and linguistic properties of the recorded encounter to surface screening signals for mild cognitive impairment and Alzheimer's disease (Canary Cognitive) and for depression and anxiety (Canary Behavioral), with no separate application or added step during the visit. Canary describes the output as clinical decision support for a clinician to interpret, not a diagnosis, and states that Marketplace listing is not self service: enablement still goes through Canary for licensing and deployment.

Why it matters: The change is distribution, not the model: a health system already on Dragon Copilot can now procure and deploy voice biomarker screening through a channel its IT and legal teams have already approved, which is the step that has kept this category in pilots. The questions Canary itself says to ask are the right ones, and they belong in the contract: intended use, patient consent for biomarker analysis, audio retention and deletion, whether encounter audio trains vendor models, and performance across accent, age and language.

Impact: High. Verification: Verified. Type: EHR / interoperability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> IQVIA launched Predictive Clinical Development, a suite covering site selection and study design, an automated start up path it calls Push… https://aihealthindex.io/changelog/iqvia aihealthindex.io:change:6a9c312c04c538181acf1b41 Thu, 03 Sep 2026 12:00:00 GMT Product / capability Clinical Trials AI Clinical Decision Support IQVIA launched Predictive Clinical Development, a suite covering site selection and study design, an automated start up path it calls Push Button Start-Up, and real time data cleaning aimed at shortening the gap to database lock.

Why it matters: Each of the three targets a different well known delay, and the one worth interrogating is real time data cleaning, because database lock timelines are usually held up by query resolution rather than by query generation. Sponsors evaluating this should ask which of the three has a measured effect on an actual study rather than a modeled one.

Impact: High. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> BrainCheck added BrainCheck Screen, a pre screening tool that identifies which patients need fuller cognitive testing. https://aihealthindex.io/changelog/braincheck aihealthindex.io:change:6a9c312c04c538181acf1b40 Thu, 03 Sep 2026 12:00:00 GMT Product / capability Clinical Decision Support Behavioral Health AI Remote Monitoring & Chronic Care BrainCheck added BrainCheck Screen, a pre screening tool that identifies which patients need fuller cognitive testing. The vendor reports validation on a 99 patient dataset showing 92 percent sensitivity and 74 percent specificity for detecting cognitive impairment.

Why it matters: A stated population and both operating characteristics is more than most vendors in this index publish, and it is enough to reason about. Sensitivity of 92 percent with specificity of 74 percent is the right shape for a pre screen, since the job is to avoid missing people and to accept that a quarter of those flagged will test normal. The dataset is small at 99 patients, so the number to ask about is performance in a primary care population rather than a validation cohort.

Impact: High. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> CMS approved a New Technology Add-on Payment for Bayesian Health's FDA cleared continuous AI sepsis monitor, creating Medicare payment… https://aihealthindex.io/changelog/bayesian-health aihealthindex.io:change:6a9c312c04c538181acf1b3d Wed, 02 Sep 2026 12:00:00 GMT Regulatory / FDA Inpatient Deterioration & Risk Monitoring Clinical Decision Support Health System AI Platforms CMS approved a New Technology Add-on Payment for Bayesian Health's FDA cleared continuous AI sepsis monitor, creating Medicare payment support for health systems running the platform.

Why it matters: This is the rarest event in this index, which is an AI tool acquiring a reimbursement pathway rather than only a clearance. Clearance establishes that a product may be used and says nothing about who pays for it, and the absence of a payment mechanism is the reason most cleared clinical AI stalls after the pilot. An NTAP moves the conversation from the innovation budget to the operating one.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Xsolis launched GenAI Peer-to-Peer Clinical Synopsis as an add on inside Dragonfly Advise. https://aihealthindex.io/changelog/xsolis aihealthindex.io:change:6a9c312c04c538181acf1b3c Tue, 01 Sep 2026 12:00:00 GMT Product / capability RCM & Prior Auth AI Clinical Decision Support Xsolis launched GenAI Peer-to-Peer Clinical Synopsis as an add on inside Dragonfly Advise. It reads longitudinal EMR data including labs, vitals and nursing notes, and generates a structured synopsis highlighting severity indicators and medical necessity rationale ahead of a peer to peer denial review.

Why it matters: The vendor puts the manual version of this task at 15 to 20 minutes of chart reconstruction inside a 24 to 72 hour regulatory window, which is a specific enough claim to test against a physician advisor's own calendar. The risk to check in evaluation is what the synopsis omits, since a medical necessity argument built from a summary is only as good as the exclusions nobody sees.

Impact: Medium. Verification: Partially Verified. Type: Product / capability.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Abridge shipped its August 2026 release with four additions that push the product upstream of the encounter it was built to document. https://aihealthindex.io/changelog/abridge aihealthindex.io:change:6a92e5ef75bbcbbe469c6ff9 Fri, 28 Aug 2026 12:00:00 GMT Product / capability Ambient Scribes RCM & Prior Auth AI Clinical Decision Support Abridge shipped its August 2026 release with four additions that push the product upstream of the encounter it was built to document. Pre Visit Summaries synthesize a patient's history, active problems and recent changes before the visit, with every detail linked back to its source in the chart. Pre Admission Summaries do the equivalent for inpatient handoff, aggregating the emergency department course, labs, vitals, imaging and prior documentation into one view at the start of an admission. The release also adds transparent level of service recommendations for coding, and lets clinicians claim AMA PRA Category 1 CME credit for reviewing eligible topics at the point of care.

Why it matters: An ambient scribe that also prepares the clinician before the encounter is competing for a different budget line than one that only writes the note, and the source linking is what makes the summary usable in a setting where an unverifiable synthesis is a liability. The coding recommendation being described as transparent matters to compliance teams, since level of service suggestions that cannot be explained are exactly what draws payer scrutiny. The CME element is the genuine novelty and it is worth watching, because attaching accredited education to routine chart review changes what the tool is worth to a clinician personally rather than only to the organization.

Impact: High. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Stratipath Breast received CE marking under the European Union In Vitro Diagnostic Regulation, EU 2017/746. https://aihealthindex.io/changelog/stratipath aihealthindex.io:change:6a92e5ef75bbcbbe469c6ff1 Tue, 25 Aug 2026 12:00:00 GMT Regulatory / FDA Digital Pathology AI Diagnostics & Genomics Clinical Decision Support Stratipath Breast received CE marking under the European Union In Vitro Diagnostic Regulation, EU 2017/746. IVDR is a substantially higher bar than the IVD Directive it replaced, requiring clinical evidence, demonstrated analytical validity and an ongoing post market surveillance commitment rather than largely self declared conformity. For an AI based prognostic tool this is one of the more demanding routes to European market access currently available.

Why it matters: European pathology labs and oncology departments can deploy the tool clinically rather than for research use only, which is the practical distinction that determines whether a result can inform a treatment decision. The post market surveillance obligation is worth weight in a vendor comparison, because it commits Stratipath to monitoring real world performance rather than resting on the validation study. Buyers comparing AI pathology vendors across regions should note that IVDR certification and FDA clearance are not interchangeable and cover different claims.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Mercy and Aidoc released a white paper, commissioned by AVIA, reporting on five months of AI deployment across the Mercy health system. https://aihealthindex.io/changelog/aidoc aihealthindex.io:change:6a92e5ef75bbcbbe469c6fee Tue, 25 Aug 2026 12:00:00 GMT Clinical evidence Radiology & Imaging AI Clinical Decision Support Health System AI Platforms Mercy and Aidoc released a white paper, commissioned by AVIA, reporting on five months of AI deployment across the Mercy health system. The review documents more than 50,000 new clinical findings surfaced in that window and tracks the associated changes in speed of diagnosis and time to treatment. The scale is the notable part: this is a multi hospital deployment reporting aggregate output rather than a single site pilot.

Why it matters: A five month figure from a named health system gives buyers something to model against, which vendor accuracy claims do not. The number to interrogate is what counts as a new clinical finding, since that definition determines whether 50,000 represents meaningful catches or a high volume of flags a radiologist would have reached anyway. AVIA commissioning the work makes it more independent than a vendor case study and less independent than peer review, which is roughly where its evidentiary weight should sit.

Impact: Medium. Verification: Partially Verified. Type: Clinical evidence.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> A study was published evaluating what happened when Brainomix 360 Stroke was implemented in a high volume stroke system that already used… https://aihealthindex.io/changelog/brainomix aihealthindex.io:change:6a92e5ef75bbcbbe469c6fed Mon, 24 Aug 2026 12:00:00 GMT Clinical evidence Radiology & Imaging AI Clinical Decision Support A study was published evaluating what happened when Brainomix 360 Stroke was implemented in a high volume stroke system that already used routine perfusion imaging. The finding is that the platform improved the efficiency of the acute stroke pathway even in a setting that was not imaging constrained to begin with. The design matters here, because it is an implementation study in an operating service rather than a retrospective accuracy comparison against a reference standard.

Why it matters: Most stroke AI evidence measures whether the algorithm agrees with an expert reader, which tells a buyer very little about whether the service gets faster. This one measures the pathway, which is the thing hospital leaders are actually purchasing. The high volume, routine perfusion setting is the harder test case, since those centers have the least headroom for an AI tool to add value, so a positive result there travels further than one from an under resourced site.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Tempus received FDA 510(k) clearance for Tempus ECG PH, software that reads a standard 12 lead electrocardiogram and identifies signs… https://aihealthindex.io/changelog/tempus aihealthindex.io:change:6a92e5ef75bbcbbe469c6fec Mon, 24 Aug 2026 12:00:00 GMT Regulatory / FDA Clinical Decision Support Diagnostics & Genomics RCM & Prior Auth AI Clinical Trials AI Tempus received FDA 510(k) clearance for Tempus ECG PH, software that reads a standard 12 lead electrocardiogram and identifies signs associated with pulmonary hypertension. The device does not require new hardware or a new test, since it runs against ECGs that are already being captured for other reasons. This adds to the cleared cardiovascular algorithm suite Tempus has been assembling, and pulmonary hypertension is a deliberate target because it is characteristically diagnosed late.

Why it matters: Clearance is the gate that separates a research grade algorithm from something a cardiology service can put into routine practice, and this one runs on data every hospital already has in volume. The deployment question is what happens downstream of a positive flag, because pulmonary hypertension confirmation requires right heart catheterization and a screening tool that raises referral volume without a matching diagnostic pathway creates a bottleneck rather than removing one. Ask for the sensitivity and specificity in the cleared indication and the population it was established in.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> FDB (First Databank): FDB commercially deployed FDB Script Agent, an AI prescribing tool that converts ambient patient encounter dialogue directly into… https://aihealthindex.io/changelog/first-databank aihealthindex.io:change:6a92e5ef75bbcbbe469c6fe8 Mon, 24 Aug 2026 12:00:00 GMT Product / capability Medication Safety & Prescribing Clinical Reference & Evidence Clinical Decision Support FDB commercially deployed FDB Script Agent, an AI prescribing tool that converts ambient patient encounter dialogue directly into structured prescriptions. The agent applies FDB's drug terminology codification and clinical validation to what it hears, so the output is a coded medication order rather than free text, and it queues that order for clinician review rather than transmitting it. It launched first on the Tebra platform. This moves ambient listening past documentation and into order entry, which is a materially different risk surface.

Why it matters: Practices can cut the manual keystrokes of prescription entry, which is one of the slowest steps left in an otherwise automated encounter. The important detail for evaluators is that FDB owns the drug knowledge base underneath the codification, so the structured output inherits an established terminology layer rather than a model's guess at a drug name and dose. Anyone assessing this should focus on the review step: what the clinician sees before signing, and what happens when the agent mishears a dose or a route.

Impact: High. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> OpenEvidence launched Patient Take-Homes, a new feature allowing clinicians to optionally turn AI-generated answers into educational… https://aihealthindex.io/changelog/openevidence aihealthindex.io:change:6a89d007fbe75a71b1da7272 Thu, 20 Aug 2026 12:00:00 GMT Product / capability Clinical Reference & Evidence Clinical Decision Support OpenEvidence launched Patient Take-Homes, a new feature allowing clinicians to optionally turn AI-generated answers into educational materials for their patients. The feature enables doctors to share specific, curated clinical evidence directly with patients at their discretion.

Why it matters: This capability extends the platform's utility beyond clinician-facing decision support into patient engagement and education. Buyers can leverage this to improve patient health literacy and streamline the creation of evidence-based post-visit summaries.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> 4baseCare launched TARGT Indiegene V2, a cancer profiling panel expanded to cover 2,206 genes. https://aihealthindex.io/changelog/4basecare aihealthindex.io:change:6a89d007fbe75a71b1da7269 Tue, 18 Aug 2026 12:00:00 GMT Product / capability Diagnostics & Genomics Clinical Decision Support Clinical Trials AI 4baseCare launched TARGT Indiegene V2, a cancer profiling panel expanded to cover 2,206 genes. The updated panel is positioned by the vendor as providing precision oncology insights tailored for diverse and historically underrepresented populations.

Why it matters: Oncologists and health systems gain access to a significantly expanded genomic panel, which the vendor positions as enabling more precise targeted therapy selection for cancer patients from diverse genetic backgrounds. Reported only in trade press so far; confirm panel specifications at source before relying on them.

Impact: Medium. Verification: Partially Verified. Type: Product / capability.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Abridge announced the enterprise-wide expansion of its Context-Aware Clinical Intelligence platform, allowing partner health systems to… https://aihealthindex.io/changelog/abridge aihealthindex.io:change:6a89d007fbe75a71b1da7267 Mon, 17 Aug 2026 12:00:00 GMT Pricing / packaging Ambient Scribes RCM & Prior Auth AI Clinical Decision Support Abridge announced the enterprise-wide expansion of its Context-Aware Clinical Intelligence platform, allowing partner health systems to deploy the AI agent to every clinician across their organizations.

Why it matters: This shift to a system-wide deployment model allows healthcare organizations to scale ambient AI documentation across all specialties and users, standardizing the technology across the enterprise rather than limiting it to early adopters.

Impact: Medium. Verification: Verified. Type: Pricing / packaging.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> A retrospective single-center study published in Diagnostics externally validated several CE-certified AI systems, including Milvue's… https://aihealthindex.io/changelog/milvue aihealthindex.io:change:6a808db25e3cc8842da0dc3e Fri, 14 Aug 2026 12:00:00 GMT Clinical evidence Radiology & Imaging AI Clinical Decision Support A retrospective single-center study published in Diagnostics externally validated several CE-certified AI systems, including Milvue's TechCare Kids, for automated bone age assessment. The researchers found no significant differences in accuracy between TechCare Kids and the other evaluated AI systems for 90% of the clinically relevant pediatric cohort.

Why it matters: Prospective buyers evaluating pediatric bone age AI tools can use this independent clinical validation as evidence that Milvue's TechCare Kids performs competitively alongside other commercial solutions. The findings provide clinical reassurance of the model's reliability in standard use cases.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Peer-reviewed publication

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals… https://aihealthindex.io/changelog/paradigm-health aihealthindex.io:change:6a808db25e3cc8842da0dc3c Thu, 13 Aug 2026 12:00:00 GMT Clinical evidence Clinical Trials AI Clinical Decision Support Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals and 370 health centers. The AI-powered system connects to the EHR to continuously evaluate patient records against eligibility criteria, leading to a 41% increase in screening capacity, a 3.6-fold increase in patients identified for future trial eligibility, and a 75% reduction in manual review effort by clinical research coordinators.

Why it matters: Real-world operational metrics from a major health system provide robust evidence that this AI platform can significantly scale clinical trial screening volumes without a proportional increase in headcount. The reported 75% drop in manual effort offers a strong return-on-investment case for research administrators seeking to alleviate coordinator burnout and maximize trial enrollment.

Impact: High. Verification: Partially Verified. Type: Clinical evidence.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Ubie's AI-powered patient access tool, Smart Support, has been officially qualified on the Mayo Clinic Platform. https://aihealthindex.io/changelog/ubie aihealthindex.io:change:6a808db25e3cc8842da0dc38 Wed, 12 Aug 2026 12:00:00 GMT Regulatory / guideline Clinical Decision Support Patient Voice Agents Ubie's AI-powered patient access tool, Smart Support, has been officially qualified on the Mayo Clinic Platform. The solution evaluates routine patient interactions across phone calls, web chats, and portal messages. It autonomously determines the clinical urgency, appropriate specialty, and correct visit type at intake prior to scheduling.

Why it matters: Qualification by an independent, reputable body provides health systems with external validation of the algorithm's clinical performance and readiness for real-world workflows. Centralized patient access teams can confidently deploy the tool for high-volume intake routing to reserve staff time for complex cases requiring human judgment.

Impact: High. Verification: Partially Verified. Type: Regulatory / guideline.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> A systematic review published in npj Digital Medicine evaluated 11 studies assessing OpenEvidence's clinical question-answering… https://aihealthindex.io/changelog/openevidence aihealthindex.io:change:6a808db25e3cc8842da0dc36 Wed, 12 Aug 2026 12:00:00 GMT Clinical evidence Clinical Reference & Evidence Clinical Decision Support A systematic review published in npj Digital Medicine evaluated 11 studies assessing OpenEvidence's clinical question-answering capabilities. The researchers found that the platform consistently generated evidence-supported responses without fabricating citations, showing peak performance in structured, guideline-based settings. However, the study noted that accuracy varied in complex scenarios and that the system tended to reinforce rather than alter existing clinical decisions.

Why it matters: This peer-reviewed analysis provides buyers with independent validation of the platform's clinical safety and operational strengths. The findings suggest the tool is highly reliable for guideline-based queries but highlight the need for human oversight in complex cases where it may simply affirm prior clinical judgments.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Peer-reviewed publication

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Valar Labs and clinical partners published a peer-reviewed study in Urologic Oncology detailing the development and validation of an… https://aihealthindex.io/changelog/valar-labs aihealthindex.io:change:6a808db25e3cc8842da0dc31 Mon, 10 Aug 2026 12:00:00 GMT Clinical evidence Digital Pathology AI Diagnostics & Genomics Clinical Decision Support Valar Labs and clinical partners published a peer-reviewed study in Urologic Oncology detailing the development and validation of an image-only AI prognostic biomarker for muscle-invasive bladder cancer (MIBC). Built on the company's Computational Histopathology Artificial Intelligence (CHAI) platform, the model extracts features from pre-treatment H&E-stained whole slide images to risk-stratify patients for recurrence-free, cancer-specific, and overall survival.

Why it matters: Clinical evidence is critical for evaluating AI diagnostics. This validation demonstrates that Valar Labs' underlying CHAI technology can derive meaningful prognostic signals from standard, already-collected pathology slides in MIBC patients, offering oncologists an additional data point for treatment planning without requiring separate molecular tests.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Peer-reviewed publication

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Creyos announced real-world outcomes from its deployment across more than 35 sites at Claremedica, a value-based primary care organization… https://aihealthindex.io/changelog/creyos aihealthindex.io:change:6a808db25e3cc8842da0dc2f Mon, 10 Aug 2026 12:00:00 GMT Clinical evidence Clinical Decision Support Behavioral Health AI Diagnostics & Genomics Creyos announced real-world outcomes from its deployment across more than 35 sites at Claremedica, a value-based primary care organization serving over 34,000 Medicare Advantage patients. Over a seven-month period, replacing the paper-based MMSE with Creyos' digital cognitive assessment enabled Claremedica to identify over 90% of new dementia cases at the early or mild stages while reducing average screening times from roughly 12 minutes to six minutes.

Why it matters: Value-based care buyers evaluate digital screeners on both operational efficiency and diagnostic sensitivity. This named health system outcome validates that the platform can halve administrative screening time without sacrificing clinical rigor, enabling earlier intervention and proactive care planning for Medicare Advantage populations.

Impact: High. Verification: Partially Verified. Type: Clinical evidence.

Evidence: Vendor documentation

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]>